Editorial Review
Author: Dr. Elena Vasquez, Ph.D.(Ph.D. Biochemistry · Lead Science Editor)|Reviewed by: Scientific Compliance Reviewer
Last reviewed: April 2026
Definitions in brief
GLP (Good Laboratory Practice) is a quality system for non-clinical safety studies, historically associated with regulatory submission packages. cGMP (current Good Manufacturing Practice) is a system for the manufacture of products where consistent batch quality and controls are the goal (including many pharmaceutical contexts).
When a reagent is sold for general research (RUO), a vendor may or may not describe internal manufacturing in cGMP-like terms. The practical question for the buyer is what batch documentation (COA, test methods) supports the acceptance criteria in the research protocol, not a generic buzzword. See how to read a peptide COA.
Researchers comparing retailers can also use the vendor comparison pillar for the methodology PurePep Vital uses in editorial content.
Important Disclaimer — For Research Use Only
The information provided is for educational and research purposes only. All peptides discussed or linked on this site are intended strictly for laboratory and scientific research use only (RUO) and are not for human consumption, injection, ingestion, or any therapeutic application. These products have not been evaluated or approved by the FDA or any regulatory body and are not intended to diagnose, treat, cure, or prevent any disease or condition. Reliance on this content is at your own risk. Consult qualified professionals for any health-related decisions. PurePep Vital disclaims all liability for misuse. Products are offered by third-party retailers for research use only.
PurePep Vital is an editorial publisher, vendor comparison resource, and affiliate deal tracker. We do not manufacture, compound, sell, ship, test, prescribe, or handle peptide products. Purchases are completed directly through third-party retailers. PurePep Vital is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. PurePep Vital is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
Disclosure: This page contains affiliate links. We may earn from qualifying purchases. See our full disclosure.
Need deals after the research?
Use the deals hub to compare current offers, partner codes, and research news. We recommend retailers that provide quality signals when available.
Explore Our Guides
Related Articles
Research Peptide Deals: How to Compare Vendors (RUO)
PurePep Vital helps you compare research peptide deals and retailer quality signals—not hype. Here is a practical framework before you click through.
Bacteriostatic Water for Peptides: The Complete Research Guide
Bacteriostatic water is the standard reconstitution solvent for lyophilized peptides in research settings. This guide covers BAC water composition, reconstitution technique, storage protocols, and how it compares to sterile water and acetic acid solutions.
USP Statement on HHS Peptide Policy: Quality Standards Gap for 503A Compounding
On November 3, 2026, the United States Pharmacopeia (USP) issued a public statement on the HHS enforcement discretion policy for six peptides (BPC-157, TB-500, others), stating it lacks essential quality safeguards: no USP-NF monographs, no reference standards, and no established names. Here is what USP said and why it matters for identity and purity testing.
HHS Files Peptide Enforcement Discretion Policy for 503A Compounding — Oct 2026
On October 28, 2026, HHS filed a Federal Register notice announcing enforcement discretion for state-licensed pharmacies, federal facilities, and physicians compounding with certain peptides including BPC-157 and TB-500. Here is what the policy covers, what it does not, and the timeline ahead.
Frequently Asked Questions
Not automatically. cGMP language sometimes describes a vendor’s quality system. The product is still subject to the vendor’s product designation and the buyer’s use case. RUO use remains non-clinical unless the project’s regulatory path says otherwise.